Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 20/20 | 0.67 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.62 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9554468 | 0.96 | FDPS (0.67) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| SCHEMBL9554186 | 0.92 | FDPS (0.65) | FDPSGGPS1 | |
| SCHEMBL9850898 | 0.91 | FDPS (0.77) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| SCHEMBL9772654 | 0.84 | FDPS (0.65) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| SCHEMBL9161138 | 0.81 | FDPS (0.59) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| SCHEMBL10622087 | 0.81 | FDPS (0.71) | FDPS | |
| SCHEMBL6224119 | 0.80 | FDPS (1.00) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| SCHEMBL9157516 | 0.80 | FDPS (0.57) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| SCHEMBL9642054 | 0.78 | FDPS (0.76) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| SCHEMBL9499462 | 0.78 | FDPS (0.56) | FDPSGGPS1AGTR1OPRM1PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6255288-B1 | THERAPY FOR BONE DISORDERS | NOVARTIS CORPORATION | 2001-07-03 | — | — | US | claimed |
| EP-0600834-A1 | Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing | CIBA-GEIGY AG (CH) | 1994-06-08 | — | — | EP | claimed |
| EP-0550385-A1 | Oral pharmaceutical compositions containing derivatives of methane-diphosphonic acid and 18-crown-6 ethers | CIBA-GEIGY AG (CH) | 1993-07-07 | — | — | EP | claimed |
| EP-0320455-B1 | ARALIPHATYL AMINOALCANE DIPHOSPHONIC ACIDS | CIBA-GEIGY AG (CH) | 1993-06-09 | — | — | EP | claimed |
| US-5190930-A | Calcium metabolism disorder | CIBA-GEIGY CORPORATION (US) | 1993-03-02 | — | — | US | claimed |
| US-5133972-A | TOPICALLY ADMINISTRABLE PHARMACEUTICAL PREPARATIONS | CIBA-GEIGY CORPORATION (US) | 1992-07-28 | — | — | US | claimed |
| EP-0407344-A2 | Pharmaceutical preparation for topical application | CIBA-GEIGY AG (CH) | 1991-01-09 | — | — | EP | claimed |
| EP-0320455-A1 | Araliphatyl aminoalcane diphosphonic acids | CIBA-GEIGY AG (CH) | 1989-06-14 | — | — | EP | claimed |
| US-6255288-B1 | THERAPY FOR BONE DISORDERS | NOVARTIS CORPORATION | 2001-07-03 | — | — | US | disclosed |
| US-5296475-A | Methanediphosphonic acids and crown compounds for treatment of bone disorders or hypercalcemia | CIBA-GEIGY CORPORATION (US) | 1994-03-22 | — | — | US | disclosed |
| EP-0550385-A1 | Oral pharmaceutical compositions containing derivatives of methane-diphosphonic acid and 18-crown-6 ethers | CIBA-GEIGY AG (CH) | 1993-07-07 | — | — | EP | disclosed |
| EP-0320455-B1 | ARALIPHATYL AMINOALCANE DIPHOSPHONIC ACIDS | CIBA-GEIGY AG (CH) | 1993-06-09 | — | — | EP | disclosed |
| US-5190930-A | Calcium metabolism disorder | CIBA-GEIGY CORPORATION (US) | 1993-03-02 | — | — | US | disclosed |
| US-5133972-A | TOPICALLY ADMINISTRABLE PHARMACEUTICAL PREPARATIONS | CIBA-GEIGY CORPORATION (US) | 1992-07-28 | — | — | US | disclosed |
| US-5110807-A | Calcium metabolism disorders | CIBA-GEIGY CORPORATION (US) | 1992-05-05 | — | — | US | disclosed |
| EP-0407344-A2 | Pharmaceutical preparation for topical application | CIBA-GEIGY AG (CH) | 1991-01-09 | — | — | EP | disclosed |